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The goal of this investigation was to establish meth-
odology to determine and prevent phototoxic re-
sponses of normal skin to photodynamic therapy 
(PDT). The drug used was a second-generation pho-
t osensitizer, benzoporphyrin derivative monoacid 
ring A (BPD-MA). The dependence of skin phototox-
icity on drug dose (0.5-2.0 rng/kg), fluence (1.2-390 
J/crn2 ), and wavelength (690 nm and 458 nm) was 
studied in the New Zealand albino rabbit in the first 
5 h after injection. Skin responses were recorded for 
2 wk after irradiation. Noninvasive n'leasurements of 
drug fluorescence were made on unexposed skin sites 
during the first 5 h after drug injection. Imrnediate 
r esponses to PDT included erythema induced by 458 
llII1 light and blanching induced by 690 nrn light. 
Delayed reactions included ederna on the day of 
exposure, purpura at 24 h, eschar by day 2 or 3, and 
P hoto dynamic therap y (PD T ) has been developed over the past deC". de into a p romising therap eutic modali ty for a wide range o f solid tumors (Do ugher ty, 1987 , 1993; Pass, 1993) . PDT requires the administration of a tumor-localizing photosensitizing agen t which , after 
exposure to visible light in the presence of oxygen , gives rise to 
highly reactive and cytocm..ic species including single t oxygen and 
free radicals. Both tumor and no rmal cells are susceptible to dam age 
by th ese cyto toxic species (D ougherty , 1987) . PDT efficacy is 
determined by a series o f fac tors, such as the photosensitizer 
absorption spectrum , the wavelength of ac tivating light , the p res-
ence of competing chrom ophores, the light penetration ill tissue, 
the selec tive localization of the photosensitizer , and the biologic 
response of ti ssue to singlet oxygen . 
Several PDT studies on cutaneous m alignancies as w ell as benign 
skin lesions have been carried out afte r sys temic administratio n of 
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scar by the end of follow-up. The threshold fluence 
for imrnediate responses correlated strongly with the 
threshold fluence for delayed reactions. The induc-
tion of threshold purpura on day 1 was a reliable 
index for skin photo toxicity that led to necrosis. The 
minirnum purpura dose on day 1 after irradiation 
increased exponentially with the interval between 
drug injection and irradiation, independent of irra-
diation wavelength, for all drug doses. The action 
spectrum for threshold purpura mimics closely the 
absorption spectrum of BPD-MA. The irt vivo drug 
fluorescence correlated with skin phototoxicity, thus 
allowing predictive dosirnetry. This rnodel systern 
defines the safety limits for skin phototoxicity of PDT 
with BPD-MA. Key words: action sp ectl'lllllliasedberrz opor-
phYI-irt derivatille lIIolloacid l-illg A (BPD-MA)I.flIlOl'escetlce 
spectl·oscop)'. J Invest D el'matol108:501-505, 1997 
bo th fi rst- and second-generation pho tosensitizers (Gom er, 
1991; Lui et nl, 1993) . During clinical trials, drug doses, irradia-
tio n fiuences , and flu ence rates are being chosen experimentally , 
and PDT results have been vari able (Gilson et nl, 1988; Dougherty 
and Marcus, 1992) . Maj or problem s in PDT with firs t-genera tion 
porphyrins have included prolo nged skin photosensitivity 
(Kessel et nl, 1985) and limi ted pene tration of light in tissue . T IllS 
required improvem ents of therape utic efficacy by the developmen t 
of new ph o tosensitize rs and better de terminatio n of PDT dosime-
try. 
Benzoporphyrin derivative monoacid ring A (BPD -MA), a sec-
ond-generation photosensitize r, is a semisyn thetic porphyrin pre-
pared b y the reaction of protopo rphyrin w ith dime thyl acety-
lene di carboxylate (Ri chter et nl , 1987) . BPD - MA is a potent 
lipo philic photose nsiti zer ill " it/'o (Richter et nl , 1990b) and ill 
"i,)o (Richter ef nl , 1991 a) . BPD-MA exhibi ts absorpti on m axima 
at 354, 418 , 574, 626, and 688 nm in 50% m e th ano l solu tion s. 
T he 688 nm maximum sbi fts to 692 nm in aqu eous solu tions, 
w ith an extinctio n coe ffi c ien t of34,000 M - 'cm - ' (Ri ch ter et nl , 
1990b) . BPD -MA has proved ill " i"o to be a m o re e ffi cient 
ph o tose nsitizer than hema topo rphyrin com po unds, wi th no la-
tent skin photo to x icity (Richter et nl, 1987, 1990a, 1991a, b ; Lui 
et nl, 1993 ) . 
T IllS study was designed to inves tigate the responses of normal 
skin to PDT to establish safe limi ts fo r drug and ligh t doses . 
0022-202X/97/S10.50 • Copyright 1997 by T he Society for Investigative Dermatology . Inc. 
501 
502 TSOUKAS fIT AL 
MATERJALS AND METHODS 
Photosensitizer Liposomal BPD-MA was supplied by Quadra Logic 
Technologies Inc. (Vancouvcr, Canada). Drug was protected from light and 
maintained at 4°C until usc. Liposomal BPD-MA for each experiment was 
reconstituted in stc rile water (Abbott Laboratories, North Chicago, IL) at a 
concentration o f 1.4 7 mg Iiposomal BPD per ml. T he drug was "dministered 
at 0.5, 1 , or 2 mg/ kg body weight by bolus intravenous injection in the 
peripheral car vein through a 24-gaugc angioca thcter (Bec ton DicIGnson 
Vasculat Access , S,mdy, UT) , Aushed with 2.5 ml of 5% dextrose in water 
(Baxter Hcalthcare Corp., Deerfield, IL). 
Light Delivery Systems Light was produced at 690 nm with an argon 
ion pumped dyc laser (CR 599 Dye Laser; Coherent, Palo Alto, CAl and at 
458 11m wirh an argon ion laser (Innova 100; Cohercnt) . The laser output 
was coupled into a microlcns-tipped quartz fiber (Quadra Logic Techno l-
ogies Inc.). Thc laser beam (3.6 cm in diameter) was "djusted perpendicular 
to the sIGn . T he irradiancc was 127 and "100 m W / cm2 for 690 nm and 458 
nm, respectively, and w;'s measured with a power meter (Model 210; 
Cohcrcnt) . 
An.imals T he New Zealand albino r"bbi t was the anImal model selected 
(Millbrook Breeding Farms, Amherst. MA) . Animals weighed 2-3.5 kg 
each. The study design was approved by the Subcommittee on Research 
Animal Care at the Massachusetts General Hospital. The animals were 
anesthetized during the whole procedure by intramuscular injcction of a 
mixture ofkctamine (30 mg/kg) (Warner-Lambert Co., Morris Plains , Nj) , 
xylazine (5 mg/kg) (Amcrican .R egent Labonltories. Inc., Shirley, NY) , and 
atropine (5 mg/kg) (Miles Inc., Shawnee Mission, KS). The an imals were 
re-injected with 0.4 ml of the anesthetic mixture as necessary. Fur on the 
back was clipped (Model 5-01 , size 40. Anim al C lippers; Oster, Milwau-
kee, WI) and thereafter meti culously shaved ("Baxter" razors, Mansfield, 
MA) to obtain smooth skin appropriate for irradiations and optica l rnea-
SUrCITIcnts. 
Normal Skill Phototoxicity Ve.'slIs Timc T he reproducibili ty of sIGn 
responses to PDT and the duration of normal sIGn photosensitiv'ity were 
investigated over the first 5 h after drug infusion . Animals (N = 13) were 
injected with 2 mg/kg BPD-MA and irradiatcd at hourl y in te rvals (1-5 II 
after infusion) with 690 nm at a fixcd Auence oDO j /cm2 and a fixed Auence 
ratc of 127 mW/cm2 . Irradiations were duplicated at each time point on 
either sidc on the animal's back. The irrad iated sIGn sites were 1.8 X 1.8 em 
and were outlined by an adhesive-backed aluminized mylar template (MED 
3044; DV Die C utting, Inc., Danvers, MA). A site protected from light was 
defined as the control. The exposed skin sites were symmetri ca lly located 
relative to the spine and were randomized to minimize systematic e rrors. 
Action SpeetrUl11 The minimum dose to produce purpura at 24 h aftcr 
exposure was determined at 458, 476, 488, SIS, and 690 nm . Purpura was 
defined as a red-purple discoloration of the sIGn that could not be blanched 
with the applica tion of pressure, unlike erythema that may be b lanched. 
Animals (N = 2) were injected with 2 mg/kg BPD-MA and, sta rting at 1 h 
aftc r drug injection, they were phototestcd at Au ence incrcmcnts of 1 OO'y" of 
the previous dose, on four sites 1 cm in diameter at each wavelength . All 
tests were referenced to 690 nm. Thus. each test at different wave lengths 
was bracke ted by two tes ts at 690 nm. 
Dependcnce of the Minimum Purpura Dose (MPuD) on Drug 
Dose, Light Dose, and Wavelength The MPuD at 24 h after treat-
ment was dete rmincd for exposures to light at 0-5 h after drug infusion with 
690 and 458 lUll radiation (N = 24). Six animals were treated at each 
wave lcngth and each drug dose, 0.5 mg/kg and '1.0 mg/kg. Irradiations 
were performed every hour fro m 0 to 5 h after drug i.,jcction. Light Auences 
ranged fTom 1.2 to 390 j /cm2 , delivered at 127 and 100 mW/cm2 for 
irrad iations at 690 and 45 8 nm, respectively. At each time point, four skin 
sites 1 elll in diall1c tcr were Sillluitanco li sly exposed to a range of Au c nces 
at increments of 40% of the previous dose. Unirradiated contro l sites were 
also marked on either side of tI,C animal's back. 
Clinical Evaluation of Skin Reactions T he exposed and control sites 
were observed before and afte r irradiation, at 30-min interva ls for 8 h. and 
at 1, 2, 5, and 15 d after exposure. Skin reactions were scored on the sca le 
given below . Blanching, erythema. edema , and purpura were individuall y 
g raded as foll ows : -, no reaction; ::!::: I 111ininlal response without filling the 
en tire exposed arca; 1 + , response of higher in te nsity over the entire 
exposed area, with clear margins; 2 +. more pronounced response (for 
edema , the response extended beyond the borders of the exposed site); and 
3 +, marked response extending more than 0 .5 cm from the margin of the 
exposed site. The appea rances of sca le, scab, and scar were also recorded . 
~ 
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III Vi,w Fluorcsccnce Measurements Because BPD-MA has a signifi -
cant Auorescence quantum efriciency and a significant extinction coefficient 
(55 ,000 at 430 11m and 30,000 at 690 nm) , Auorescence spectra were 
obtained i" "i"o fron1 an unexposed control skin site and frolll aH treated 
sitcs before and after exposure . Fluorescence spectra were collected with a 
fluorescence spectrophotomete r (Fluoromax ; SPEX Industries, Edison, NJ) 
equipped with a fiber bundlc assembly so that ill lI i,/" Auorescence spectra 
could be obtained fTom any site on the animal's back. During the measure-
ments, thcjoiJ1ed end of the fibe ro ptic assembly was brought in contacr witb 
the sIG n site undcr stud y. /11 lIillo excitation spectra were obtained for 
emission at 690 nm on animals injected with 2 mg/kg BpD-MA. The 
430-nm excitation maximum obta ined ill lIilro from BPD-MA solutions in 
fetal bovine serum was found to shift to 456 :t 2 nm ill vi II" because of ti,e 
competing absorption of hemoglobin at 430 nm. Emission spectra were 
obtained with excitation at both maxima of the drug absorption at 450 nm 
and 690 nm. 
Emission spectra were obtained fro m an unexposed control site with 
excitation at both 450 nm and 690 nm because of the difference in tiss ue 
penetration of these two wavclcngths. When exciting at 450 nm, the 
emission spectrum was recorded from 550 to 800 nm; when exciting at 690 
nm, the emission spectrum was recorded from 700 to 800 nm. The ill lI iva 
fluorescence signal was always corrected for the normal sIGn Auorescence 
obta ined before drug infusion. The calculated Auorescence signal presented 
here is the area under the Auorescence emission curve for either 450 or 
690 nm. 
T here are two reasons w hy the Auorescence intensity excited at 450 nm 
may be different fro m that excited at 690 nm. The first involves the 
Auoresccnce efficiency of the drug and the second the distribution of the 
drug in the sIGn . To estimate changes in Auorescence intensity due to the 
Auorescence efriciency of the drug at different wavelengths. we calibrated 
with homogeneous phantoms. Scatterin g phantoms were constructed con-
sisting ofs llspensions of micro spheres 1.06 /Lm in diameter (Duke Scientific, 
Raleigh, N C) at a concentration of 2% soljds, which simulates human 
dermis. Serial dilutions ofBPD-MA were made in the scatte ring phantoms, 
and emission spectra were collected for excitation forst with 450 nm and 
then with 690 nm. T he suspension was sha ken between repcated measure-
ments to minimize precipitation of the microspheres. 
R ESULTS 
Normal Skin Photo toxicity Versl/s Time, at Constant Drug 
Dose and Constant Light Dose The c utaneous photobiologic 
resp onses to PDT with BPD-MA at 2 mg/kg with a Auence of 30 
Jlcm 2 at 127 mW/cm 2 , 690 nm light, proved reproduc ible w hen 
treatment was delivered in the first 5 h after drug administration. 
The responses were most severe on the sites irradiated at the carly 
time points after injection and gradually d ccreased in intensity and 
duration w ith time. Skin blanc hing without edema was clearly 
v isible immediately after exposure on all skin sites treated in the 
first 4 h after dru g injection. T h e blan ching disappeared with time 
and was followed b y a prominent edema on the sites treated at 1-3 
h after drug injecti o n . Seve re e dema responses include d 1- to 2-mm 
purpuric margin s. T h e sites that were exposed 4 h after injection 
sh owed mild responses, and the sites exposed at 5 h after injection 
demonstrated minimal if any re actions (Fig 1). 
T h e skin sites that were exposed 1-4 h after drug injection 
showed edema and purple-red purpura 1 d after treatment. The 
purpura induce d on the sites treated 1-2 h after injection appeared 
d eep er and were bluish-white; on the sites treated 3-4 h after 
injection, the purpura was more re d in appearan ce. The purpura 
induced in the sites exposed 4 h after injection often showed a 
superficia.l meshwork of thrombosed vessels. T he purpuric reac-
tions became deep gray-brown by day 2 after treatme nt, with arrest 
of hair regrowth . T h e ring of erythema that surrounded the cdem a 
response at day 1 d eveloped into purpura. Eschar started fonning 
on day 2 and progressed in to a c oncave, dark purple-brown scab 
approximately h alf the size of the originally exposed site. When the 
cschar was removed 15 d after exposure o n the threshold purpura 
doses, there was a Aat atrophic scar that appeared pink-yellow and 
glossy . Sites that were treated 5 h after drug inj ection showed slight 
e d e m a o n days 1 and 2 afte r exposure, accompani ed at times by 
slight purpura or eryth ema, and retumed to normal shortly there-
after. 
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Figure 1. Skin responses to PDT with BPD-MA decrease rapidly 
with time after inj ectioll. T he early rcsponse of blanching shows good 
correlation with the delayed reactions of edema (4 It) and purpura (24 h). 
The intensity of the blanching reaction (0) is expressed in terms of its 
duration (min). Edcma (~) and purpura (_) were graded on a 0-3 scale. 
Phototoxicity was induced with 30 j /cm 2 ('1 27 mW/cm2 ) of 690 nm 
radiation after injection of2 mg/kg of drug. Error bars: ± SD, N = 13. 
Action Spectrum for MPuD Follows Closely the Absorption 
Spectrum of t he Drug T he thresho ld respo nses at all wave-
lengths tested we re comparable. At 690 11m and with doses higher 
tban the Ml)uD, the skin responses extended beyond the limit of 
exposure in a concentratio n-dependent m ,mner. At the shorter 
wavelengths, the purpura was always con fi ned within the limits of 
eJ\.'posure. T h e thresh old f1uen ce for purpura was m inimum at 458 
and 690 nm. T h e results are plotted as the reciprocal of th e MPuD 
and correlate w ell with the absorptio n spectrum of the drug (Fig 2) . 
The MPuD Is Strongly D e pendent on the Injected Drug 
, Dose and the Light Dose; It Is Independent of the Wave-
length of Irradiation T he MPuD was the sam e as the f1u en ce to 
produce skin necrosis (scab) on day 2-3 and scar 0 11 day 15 (Fig 3a) . 
T he MPuD increased quickly with time after injection (exponen-
tially) and was fOlmd to be wavelength independent at both drug 
doses tested (0.5 and 1.0 m g/kg) (Fig 3b) . It is important to note 
that a lth ough the MPuD was the same at the two wavelen gths 
tested, the photobio logic responses before necrosis and the extent 
and depth of damage were significantly difFerent. T h e MPuD , 01] 
the other hand, showed a stronger than lin ear dependen ce on the 
injected drug dose. When the d rug dose was do ubled , the MPuD 
decreased by a fac tor of 4. 
Effects of 690 nm Light Exposures at MPuD with 690 nm 
radiation produced immediate blanching, which lasted fo r a few 
minutes (with no edema). At 2.5 h after exposure , the blanching 
was fo llowed by 1 + edema, which develo ped into purpura that 
comple tely filled the exposed site 24 h after exposure (Fig 4a) . 
Superthresho ld exposures produced a concave scab , the diameter of 
, which increased with increasing dose. 
Effects of 458 11m Light T h e overa ll responses of the skin to 
458 nm radiation were milder than those produced by 690 nm 
radiation. At MPuD, a mild di ffuse e rythema ( ± ) appeared imme-
diately after exposure, which was followed by edema (1 + ) at 6-7 h 
(Fig 4b). At 24 h after exposure, the site h ad purpura (reddish- ligh t 
brown). Skin sites irradiated at a dose 40'Xl lower than th e MPuD 
showed a superficial light brow nish discoloration that resolved . 
Supertiueshold exposures produced a flat scab , th e diameter of 
which rem ained constant with in creasing dose. T he severity of 
damage that fo llowed the 24-h purpura was m ore intense for 690 
nm th an for 458 11m radiation . 
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Figure 2. The absorption spectrum of BPD-MA ;/1 IIityo and the 
fluorescence excitation spectrum ofBPD-MA ;11 11;110 for emission at 
690 11m have very si.milar features. The differences in the two spectra 
are due to the absorption ofhemoglobiu. T he two spectra are normalized at 
620 nm, as there is little contribution by hemoglobin at that point. T he ill 
"ill() excitation spectrum (solid fiu e) ofBPD- MA indicates absorption m<Lxima 
at 456 ::!: 2 and 690 11m; these wavelengtlu were therefore selected fo r 
treatments. T he reciprocal of the Auence to produce tlueshold purpura data 
on day 1 (6 ) is also plotted along with the absorption spectrum (dotted liue). 
Note tl,at the action spectrum fo llows ti,e genera] fea tures of the absorption 
spectrum. INT., intensity. (N = 2). 
Noninvasive Fluorescence Closely Follows Phototoxicity 
T he excitation fluorescen ce spectrum of BPD-MA ill villo was 
o b ta ined from animals inj ected with 2 m g/kg (Fig 2). It proved 
som ewh at different from the absorption spectrum because of 
attenuation of the excitation ligh t by h emoglobin . The native 
fluorescence obtained from the animal' s skin before drug infusion 
with excitation at 450 or 690 nm proved stable and reproducible . 
Spectra obtained after in fusion w ere corrected fo r n ative fluores-
cen ce of the skin and yielded spectral features characteristic of the 
fluorescen ce of BPD-MA. T he fluorescen ce etnission m aximum 
and band width rem ained constant witl1 time after infusion. For 
exposures with a single f1u en ce of 30 J/cm 2 in the first 5 h after 
injection, a time-dependen t decrease of fluores cence emission 
signal was foun d , w h.ich corresponded to decreased photo toxicity 
of the animals' skin w ith time . In the experiments to determine the 
MPuD, flu orescen ce emission spectra w ere collected at 0-5 h after 
infusion from a control site on each animal. 
T h e integrated fluorescen ce obtained fro m the ho mogeneous 
phantoms excited at 450 tun was 11 .1 tim es greater than the 
corresponding flu orescence excited at 690 nm. Once tlus correction 
h as been applied to the integrated fluorescen ce obtained if/. lI i llO, the 
two signa ls m ay be displayed on the sam e scale (Fig 5 a., b). 
Fluorescence emission upon excitation at 450 nm showed a sub-
stantially slower decrease with time after inj ection compared w ith 
the fluorescen ce sign al with excitation at 690 nm. T he integrated 
fluorescence intensi ty increased linearly with drug dose. 
DISCUSSION 
Photobiologic skin responses to lipophilic photosensitizers have 
been investigated previously (Moore elal , 1986; Razum ef aI, 1987 ; 
Belln.ier and Dougherty, 1989; Henderson and Dougherty, 1992) . 
T he effi cacy of PDT with hem atop o rphyrin compo unds has been 
evaluated on tumor m odels (van Gem ert cf aI, 1985; Dougherty, 
1987; Fingar and H enderson, 1987), including the w avelength 
dependen ce (Star el aI, 1990). In this study, a systematic approach 
was u sed to de termine the dosimetry of photodynanuc drugs on 
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Figure 3. The rniniJnulll purpura dose 
is independent of wavelength for all 
time points and for all drug doses. (a) 
Al1im als were il1jected with I mg/ kg 
I3PO-MA and were treated with 690 11m 
(eire"'s) and 458 nm (tria llgll's) light at 127 and 
100 mWlcm 2 , respective ly, from 0 to 5 h 
after injection. Solid ,"arkers, threshold induc-
ing necrosis obse rved by day 'I S; "1"'11 ,"ark"rs, 
threshold fo r day 'I purpura . h) Animals were 
treated with 1 mg/kg (cirrl" s) and 0.5 m g/kg 
(Irial/gles) BPO-MA w ith either 690 n l11 light 
(so lir! 'I/"rhers) o r 458 11111 li ght (01'1'11 I/, arhen). 
L ilies represen t the best fits through the 
expel'imcntal points. Error h(/l's: :':SO, N = 6. 
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no rmal skin . BPD-MA, a potent lipophilic second-generation pho-
tosensitizer, was used to determine the acceptable limi ts of dru g 
and light to avo id phototoxicity in normal skin. We determined 
tha t skin responses of this anim al model were sta ble, reproducible, 
and simil ar in expression to those of no rmal human skin (Lui ci ai, 
1993 ) . In hnm <1 n skin, the imm ediate respo nse included a whea l and 
Aare reaction; the Aare subsided with ti.me whereas the edema 
rem ained for several days. Purpura that appeared by day 2 fre-
quently resul ted in non11al skin necrosis. T he dm g doses inves ti-
gated and reported here were selec ted so that the lig ht doses 
necessa ry for the formation of purpura were not less than 1 J/cm 2 
immed iately after injection (lOs exposure) and not 1110re than 250 
j/cm2 at 5 h after inj ection (45 min exposure). 
Constant Drug Dose and Constant Light Dose Allow De-
termination of the Range of Photobiologic Skin Reactions 
kin phototoxicity decreased rapidl y with time after dru g injection 
at all d l'ug doses . T he photobiologic respo nses of immediate 
blan ching, de layed ede ma, and gross sparing of the epidermis on 
the day of exposure, as well as purpura o n day I, indicate that the 
PDT action of this drug takes place in the skin vasculature. T he 
rapid decrease of skin phototoxicity after bolus injection of the drug 
(even at 'high doses of 2 mg/kg), due to a constant irradiation 
Au ence, al so reinforces the dependence of the PDT eft:ect on the 
circula ting drug co ncentration . 
H e moglo bin in the skin appears to play 3n important ro le in 
determining tile effective absorption of the drug in ti ssue. T his 
became clear w hen we compared the excitation Auorescence 
spectrum of the drug in the skin with the absorption sp ectrum of 
the dru g in fe tal bovin e serllm (Fig 2). The ratio of these spectra 
yielded the spectrum of hemoglobin . T he action spectrum for the 
MPuD was found to track the absorption spectrum (Waterfie ld et 
ai, 1994). 
The Treat.ment Wavelength Selects the Extent of Damage 
But Not the Light Dose to Produce Toxicity T he two 
wavelengths inves tigated, blue and red (458 and 690 nm), induced 
phototoxicity at simil ar threshold Allences for both drug doses 
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explo red . The extent of necrosis (beyond the limits of exposure) 
prod uced w ith superthreshold Auen ces at 690 n111 light appeared 
more profound than that produced with 458 nm light. In this sense, 
the biologic responses parallel the depth o f penetration of the t"vo 
wave lengths. It is also interestin g that the early vascular responses 
induced by these two wavelengths were diametri cally opposite. 
Immediately after exposure , the red light induced blanching, 
whereas the blue light induced erythema. Although tile attenuation 
of th e incident light in skin at these two wave lengths is different by 
a factor of 4 (Anderson and Parrish , 1981 ), the threshold Auence for 
purpura and eventual skin necrosis proved to be the same. The 
MPuD proved a lI sefi.'] clinical end point for photo toxicity, however. 
Because the early responses (blan ching with 690 nm and erythema 
with 458 nm) correlated well with late responses, they could be used 
to predict the threshold Auence for purpura. One can envision 
performing a phototest on a small site (e.g., 4 111m) to determine the 
blanching threshold before proceeding with treatment of a large area. 
The Drug Fluorescence Measured [II Vi"" Is Closely Related 
to Phototoxicity R.esllits showed that the 450-nm excited flu-
o rescence did not change very much with time after dru g injection, 
whereas the 690-nm excited Auorescence showed a significant 
decrease with time. Skin levels of BPD-MA remain essentially 
constant over the first 5 h after injectio n , while the plasma level 
changes as an exponential function of tim e (Richter e/ nl, 1994) . 
R adiation of wavelength 450 nm penetrates 4 times less than 
690-nm radiation (Anderson and Parrish , 1981); furth ermore, 
450-nm radiation is atten uated by hemoglobin, resulting in little 
Au orescence from the circulating drllg. In contrast, Auorescence 
excited with 690 nm radiation would probe both the epidermis and 
dennis, which would include the plasma drug concentration, as tlli 
wavelength is not attenuated by the absorption of hemoglobin. 
Therefore, by subtra cting the ti ssue contribution (450-nm excited 
Auorescence at 5 h after injecti on) fi'om the signa l o btained from 
ti ssue plus blood (690-nm excited Allorescence) , we should obtain 
a signa l th at is associated primarily with the pl asma contribution. 
T hen the corrected Auorescence at each time point can be plotted 
l/erSllS the corresponding threshold dose for pUrpl11'3 formfltion for 
both drug doses used (0.5 and 1 m g/kg) (Fig 6). W e ca n thus 
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Figure 4. The early and late photo-
toxic reactions to PDT correlate 
strongly for both red light and blue 
light. (a) The ea rl y skin reaction (blanch-
ing , trial/.~/es) and late skin reactions (4-h 
edema, 0 ; 24-h purpura, e) to PDT with 
I3PD-MA correiate closely for exposures to 
690 nl11light at 127 mW/cm 2 • Lilies re pre-
sent the best fits through the experimental 
points. (b) The ea rl y skin reacti o n (erythe-
ma . lrintwles) and late skin reactio ns (7-11 
edema, 0 ; 24-h purpura, e) to PDT with 
BPO-M A correlate closely for exposures to 
458 11m li g ht. Lilies represent the best fi ts 
through the experimenta l points. Err(lr bars: 
:':SD, N = 6. 
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define a region of safety in Fig 6 as the part below the curve and a 
region of inductio n of skin necrosis above the curve . A range of safe 
fluence valu es is defined based on ; 11 11;110 fluorescence m easure-
ments at all time points and fo r both drug doses. 
For effective dosimetry with PDT on normal skin, we must 
es tablish (i) th e phototoxic response of skin to tbe drug under a 
constant ligh t and drug "egimen, scoring individually all the skin 
reac tions; (ii) the thresho ld dose of light at di ffe ren t wavelengths 
(where the drug absorbs significantly) to produce irreparable 
damage; (iii) whether noninvasive optical m eans exist that allow 
the determination of safe dosimetry for normal skin ; and (iv) 
k translation of results obtain ed from other species to the human case. 
Once the parameters that spare normal skin have been established , 
one Call proceed w ith confidence to treat skin diseases. BPD-MA 
has been characterized, a.nd the extent of dama ge can be 
adequately described by tbe thresho ld fluen ce to produce pur-
pura (MPuD). T he thres ho ld phototox ic flu ence increases with 
time almost expo n entiall y, independent of the wave length of 
~ expos ure (red o r blue). T he ea rl y expression of phototoxicity 
an d severity of damage are different for blue and red light. 
Fluorescence measured ;11 11 ; 110 can be used to predict correctly 
the safe limits of light dose. 
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Figure 6. The corrected fluorescence correlates with the MPuD 
and allows the prediction of safety levels. T he integrated Auorescence 
excited at 690 nm , normalized for Auorescence efri ciency and corrected for 
tbe tiss ue componem by sub tracting the Auorcscence excited at 450 nm 
at 5 h aft,? r dru g injection , at both dru g doses of 0.5 m g/kg (_) and 1.0 . 
mg/kg (e), corre lates with the MPuD . Lill e represents the bcst fit to th e 
experimental points and defUlcs the limit of phototoxicity. Doscs that COlTC-
spond to points that lie between the cxperimenta l line and the horizontal axis 
are safe, whereas doses above the line would produce necrosis. (N = 6). 
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Figure 5. The ill vivo drug fluorescence 
excited with 690 nm dec.reases with time 
after drug injection, ,vhcrcas that excited 
at 450 11ln remains constant. T he integrated 
ill II i" o drug Auorescence excited at 690 nm (e) 
at 1 mg/ kg (a) and 0.5 m g/kg (b) shows a 
decrease over time , compared with the signal 
obta ined w hcn excited at 450 nm (0 ) . T he 
experimenta l points represent areas under the 
Au orcscence emission curve corrected for the 
skin fluo rescence before drug injection and 
were normalized fo r fluo rescen ce efricicl1cy at 
450 and 690 nm. Em)r bars: :tSD, N = 6. 
Time (hours) 
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